They have a Phase 2 trial for Cirrhosis starting in Q2 2017, at which time NVTS will likely exercise their partnership option for Emricasan moving forward-they will be committing as much as $650M towards the eventual approval of the drug through Phase 3.
Once they announce the start of the Phase 2 trial the stock is likely to fly, I've been buying recently in the $5 range, I originally bought a bunch of shares at $2 after the GALT FX debacle in September
staccani has some great due diligence on this stock on the CNAT board if you are interested in doing some research
News 
Market Data 
Discover 
